Literature DB >> 17114845

Differential patterns of memory performance in relapsing, remitting and secondary progressive multiple sclerosis.

Marina A Drake1, Adriana Carrá, Ricardo F Allegri, Geraldine Luetic.   

Abstract

BACKGROUND: Memory dysfunction is common in multiple sclerosis (MS). A retrieval failure has been reported as the primary cause for the memory deficits, although some studies also described a faulty acquisition. AIMS: The aim of the study was to examine memory function in relapsing remitting (RR) and secondary progressive (SP) MS patients, analyze the patterns of performance and to investigate whether disease course influences this performance. DESIGN AND SETTINGS: Case-control prospective study conducted in a clinical setting.
MATERIALS AND METHODS: Fifty-five RR, 23 SP MS patients and 80 normal subjects were evaluated with a comprehensive neuropsychological battery. Memory was assessed with tasks from the Signoret memory battery. Attention and executive function were also assessed. STATISTICAL ANALYSIS: Univariate analysis of variance, Mann-Whitney U-test, multivariate logistic regression and Chi-square test were used as appropriate.
RESULTS: MS patients performed significantly worse than controls on almost all measures of memory (P < 0,001). MS subgroups differed in tasks of delayed recall (logical memory- P =0,019; wordlist delayed recall, P < 0,001), semantic cued recall (P < 0,001), recognition trials (P =0,006) rate of forgetting (P < 0,001) and confabulation and intrusion errors (P =0,004).
CONCLUSIONS: Memory is consistently impaired in MS patients and disease course differentially affects the pattern of performance. SP patients show greater difficulties and a more pervasive pattern of dysfunction than RR patients. Delayed recall was the most affected memory measure and performance on this task discriminates between RR and SP MS patients. Relapsing remitting patients performed within the mildly impaired range while SP patients showed a moderate to severe impairment.

Entities:  

Mesh:

Year:  2006        PMID: 17114845     DOI: 10.4103/0028-3886.28108

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  8 in total

1.  Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE.

Authors:  Marina O Ziehn; Andrea A Avedisian; Seema Tiwari-Woodruff; Rhonda R Voskuhl
Journal:  Lab Invest       Date:  2010-02-15       Impact factor: 5.662

2.  Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis.

Authors:  R S Prakash; E M Snook; J M Lewis; R W Motl; A F Kramer
Journal:  Mult Scler       Date:  2008-08-13       Impact factor: 6.312

Review 3.  Working Memory Deficits in Multiple Sclerosis: An Overview of the Findings.

Authors:  Zoe Kouvatsou; Elvira Masoura; Vasilios Kimiskidis
Journal:  Front Psychol       Date:  2022-04-28

4.  Vitamin D3 attenuates oxidative stress and cognitive deficits in a model of toxic demyelination.

Authors:  Sepideh Tarbali; Shiva Khezri
Journal:  Iran J Basic Med Sci       Date:  2016-01       Impact factor: 2.699

5.  Myelin injury induces axonal transport impairment but not AD-like pathology in the hippocampus of cuprizone-fed mice.

Authors:  Junjun Sun; Hong Zhou; Feng Bai; Qingguo Ren; Zhijun Zhang
Journal:  Oncotarget       Date:  2016-05-24

6.  Progressive multiple sclerosis, cognitive function, and quality of life.

Authors:  Helene Højsgaard Chow; Karen Schreiber; Melinda Magyari; Cecilie Ammitzbøll; Lars Börnsen; Jeppe Romme Christensen; Rikke Ratzer; Per Soelberg Sørensen; Finn Sellebjerg
Journal:  Brain Behav       Date:  2018-01-05       Impact factor: 2.708

Review 7.  Cognitive and neuropsychiatric disorders among MS patients from Latin America.

Authors:  Sandra Vanotti; Fernando J Caceres
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-09-25

Review 8.  Structural Plasticity of the Hippocampus in Neurodegenerative Diseases.

Authors:  Poornima D E Weerasinghe-Mudiyanselage; Mary Jasmin Ang; Sohi Kang; Joong-Sun Kim; Changjong Moon
Journal:  Int J Mol Sci       Date:  2022-03-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.